Bicara Therapeutics (NASDAQ:BCAX) Given New $16.00 Price Target at Wells Fargo & Company

Bicara Therapeutics (NASDAQ:BCAX) had its price target boosted by Wells Fargo & Company from $11.00 to $16.00 in a research note released on Tuesday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

A number of other equities research analysts also recently commented on BCAX. Citigroup assumed coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They issued an “outperform” rating on the stock. HC Wainwright boosted their target price on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday. UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Bank of America initiated coverage on Bicara Therapeutics in a research note on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, Mizuho raised Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $28.00.

Bicara Therapeutics Stock Performance

Shares of Bicara Therapeutics stock opened at $19.89 on Tuesday. The business has a 50-day simple moving average of $17.21 and a 200-day simple moving average of $16.67. Bicara Therapeutics has a one year low of $7.80 and a one year high of $20.25. The company has a market cap of $1.09 billion, a PE ratio of -7.86 and a beta of -0.78.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.04. On average, sell-side analysts predict that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insider Activity at Bicara Therapeutics

In related news, CFO Ivan Hyep sold 9,200 shares of the stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $18.52, for a total value of $170,384.00. Following the transaction, the chief financial officer directly owned 145,355 shares of the company’s stock, valued at $2,691,974.60. This trade represents a 5.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Claire Mazumdar sold 1,596 shares of Bicara Therapeutics stock in a transaction on Friday, March 20th. The stock was sold at an average price of $18.95, for a total transaction of $30,244.20. Following the sale, the chief executive officer owned 339,392 shares in the company, valued at $6,431,478.40. This represents a 0.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 137,969 shares of company stock worth $2,586,198 in the last ninety days.

Hedge Funds Weigh In On Bicara Therapeutics

Several hedge funds have recently made changes to their positions in the company. Vestal Point Capital LP grew its holdings in shares of Bicara Therapeutics by 2.0% during the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after purchasing an additional 100,000 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Bicara Therapeutics by 596.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after purchasing an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $44,484,000. Vanguard Group Inc. boosted its position in shares of Bicara Therapeutics by 9.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock valued at $34,753,000 after purchasing an additional 195,667 shares during the period. Finally, State Street Corp grew its stake in Bicara Therapeutics by 179.5% during the 4th quarter. State Street Corp now owns 1,649,537 shares of the company’s stock worth $27,762,000 after buying an additional 1,059,260 shares during the last quarter.

Bicara Therapeutics News Summary

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Phase‑3 advancement and clinical catalysts: Bicara selected a 1,500 mg weekly dose of ficerafusp alfa and has initiated the pivotal FORTIFI‑HN01 trial with interim Phase‑3 readout expected mid‑2027; long‑term Phase‑1b follow‑up is slated for ASCO 2026 — these program milestones underpin upside potential. Article Title
• Positive Sentiment: Corporate update & financials: Q4/FY‑2025 release highlighted a strong cash position, selection of the Phase‑3 dose, and a less‑frequent dosing regimen in development — gives runway to reach clinical milestones. Article Title
• Positive Sentiment: Strong buy-side analyst support from some firms: HC Wainwright reiterated a Buy and boosted its PT to $42; Citizens Jmp and Wedbush reaffirmed market/outperform views with $31 and $30 targets — these bulls can attract momentum buyers. Article Title
• Neutral Sentiment: Modest Q4 beat: Bicara reported EPS of ($0.68) vs. consensus ($0.72) — a small beat but still operating at losses as expected for a clinical‑stage biotech. Press Release
• Neutral Sentiment: Mixed mid‑range analyst moves: Goldman Sachs and Wells Fargo raised price targets to $16 but kept Neutral/Equal‑Weight ratings (their PTs sit below the current trading level), which tempers upside for cautious investors. Article Title
• Negative Sentiment: Insider sale: CEO Claire Mazumdar sold ~8,234 shares (~$154k) in early March, trimming her direct holdings — a small insider sale but some investors view insider selling as a cautionary signal. Article Title

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.